Originally discovered in 1979, epithelial cell–adhesion molecule (EpCAM, CD326), type I, transmembrane, 39–42 kDa glycoprotein, was first described as a dominant antigen in human colon carcinoma.1 EpCAM is frequently expressed in human epithelial tumors, mainly in adenocarcinomas and other carcinomas, and it is also stably expressed and even upregulated during the progression of cancer.2 The role of EpCAM is not limited to cell adhesion; it is also involved in cellular signaling, cell migration, proliferation, and differentiation.3,4 EpCAM can be used as a prognostic marker. This evidence concerns the gene EPCAM and adenocarcinoma.